CAS No. :	74863-84-6
Formula :	C₂₃H₃₆N₆O₅S
M.W :	508.63
SMILES Code :	O=C([C@@H]1N(C([C@@H](NS(=O)(C2=CC=CC3=C2NCC(C)C3)=O)CCCNC(N)=N)=O)CC[C@@H](C)C1)O
Synonyms :	MCI-9038; MD-805; Argipidine
MDL No. :	MFCD23102419

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H312-H319-H332
Precautionary Statements:	P280-P305+P351+P338

PC-3	10 µM, 50 µM, 100 µM	24 h	To evaluate the inhibitory effect of Argatroban on the E2F1:MTA1 complex and its impact on HAS2 expression. Results showed that Argatroban significantly reduced HAS2 transcript and protein levels without affecting E2F1 and MTA1 expression.	Theranostics. 2019 Feb 20;9(5):1490-1509.
SK-Mel-147	10 µM, 50 µM, 100 µM	24 h	To evaluate the inhibitory effect of Argatroban on the E2F1:MTA1 complex and its impact on HAS2 expression. Results showed that Argatroban significantly reduced HAS2 transcript and protein levels without affecting E2F1 and MTA1 expression.	Theranostics. 2019 Feb 20;9(5):1490-1509.
Murine lung epithelial cells	100 nM		Argatroban inhibited Morf4l1-dependent histone acetylation, reduced its cytotoxicity, and improved survival of mice with experimental lung injury at doses that had no anticoagulant activity.	Sci Transl Med. 2015 Oct 28;7(311):311ra171.
Platelets	0.4-16 μg/mL	30 minutes	To evaluate the effect of Argatroban on VITT IgG binding to PF4, results showed Argatroban at therapeutic concentrations did not significantly inhibit VITT IgG binding to PF4	Blood Adv. 2024 Nov 26;8(22):5744-5752.

NMRI nude mice	Melanoma metastasis model	Intraperitoneal injection	9 mg/kg	Every other day for 4 weeks	To evaluate the inhibitory effect of Argatroban on melanoma metastasis in vivo. Results showed that Argatroban significantly reduced the formation of lung metastases and decreased HAS2 expression and infiltration of tumor-associated macrophages.	Theranostics. 2019 Feb 20;9(5):1490-1509.
Mice	Experimental pneumonia model	Intratracheal	5 µg/mouse	Single dose, for 24 hours	Argatroban inhibited Morf4l1-dependent histone acetylation, reduced its cytotoxicity, and improved survival of mice with experimental lung injury at doses that had no anticoagulant activity.	Sci Transl Med. 2015 Oct 28;7(311):311ra171.
DdY mice	Oxaliplatin-induced peripheral neuropathy model	Intraperitoneal injection	10 mg/kg	Single administration	To evaluate the impact of thrombin inhibitor on TMα's anti-neuropathic activity	J Neuroinflammation. 2019 Oct 30;16(1):199.
Mice	K/BxN transgenic mice and serum transfer-induced arthritis (STIA) model	Ex vivo co-incubation	350 µM	Single treatment	Argatroban inhibited the fluorescence signal of RACPP NleTPRSFL, indicating that it reduced probe cleavage by inhibiting thrombin activity.	Arthritis Rheumatol. 2018 Jan;70(1):69-79
C57BL/6J mice	Carotid artery thrombolysis stroke model (iCAT)	Intravenous	80 mg/kg bolus; 40 mg/kg/min infusion over 60 minutes	Single administration, duration of 60 minutes	To evaluate the effect of argatroban combined with rtPA on thrombolysis and recanalization. Results showed that argatroban increased recanalization rates to 50%, but also increased carotid artery embolization and stroke-related mortality.	Blood Adv. 2022 Sep 27;6(18):5449-5462
Mice	VITT mouse model	Osmotic pump	120 μg/kg/h	Continuous infusion	To assess the effect of Argatroban on thrombosis in VITT mice, results showed Argatroban significantly reduced clot formation but did not ameliorate thrombocytopenia	Blood Adv. 2024 Nov 26;8(22):5744-5752.
Mice	Bleomycin-induced pulmonary fibrosis model	Intraperitoneal injection	9 mg/kg	Daily for 14 days	Argatroban significantly improved the survival of PN-1?/? mice by inhibiting thrombin activity, reducing the accumulation of inflammatory cells and platelets in the lungs.	Blood Adv. 2018 Sep 25;2(18):2389-2399

NCT00603824	Heparin-Induced Thrombocytopen... More >>ia Less <<	Phase 4	Withdrawn(PI relocated)	-	-
NCT01911624	Staphylococcus Aureus Bacterae... More >>mia Less <<	Phase 2	Completed	-	Belgium ... More >> KUleuven/UZ Gasthuisberg Leuven, Belgium, 3000 Less <<
NCT00921856	Coronary Vasospasm ... More >> Microvascular Angina Coronary Artery Disease Less <<	Not Applicable	Recruiting	December 2019	Germany ... More >> Robert Bosch Medical Center Recruiting Stuttgart, Germany, 70376 Contact: Peter Ong, MD +4971181016048 petereong@gmail.com Contact: Anastasios Athanasiadis, MD +4971181015444 Less <<
NCT01162824	Endothelial Dysfunction ... More >> Atherosclerosis Inflammation Myocardial Ischemia Less <<	Not Applicable	Unknown	December 2011	United Kingdom ... More >> Department of Cardiology, St George's Healthcare NHS Trust Recruiting London, England, United Kingdom, SW17 0RE Contact: Peter E Ong, MD +44208725 ext 2628 pong@sgul.ac.uk Sub-Investigator: Peter E Ong, MD Less <<
NCT02935530	Gynecologic Neoplasms ... More >> Venous Thromboembolism Low Molecular Weight Heparin Argatroban Less <<	Phase 3	Unknown	December 2017	China, Hubei ... More >> Tongji Hospital Recruiting Wuhan, Hubei, China, 430000 Contact: Danhui Weng, M.D. 027-83663351 dhweng@tjh.tjmu.edu.cn Less <<
NCT03735979	Acute Ischemic Stroke	Phase 3	Not yet recruiting	April 2023	United States, Ohio ... More >> University of Cincinnati Medical Center Not yet recruiting Cincinnati, Ohio, United States, 45267 Contact: Natalie Kreitzer, MD kreitzne@UCMAIL.UC.EDU Less <<
NCT01304238	-		Completed	-	-
NCT01304238	-		Completed	-	-
NCT00508924	Coronary Artery Disease ... More >> Angina, Unstable Less <<	Phase 2	Completed	-	Belgium ... More >> Aalst, Belgium Germany Bad Nauheim, Germany Cologne, Germany Dachau, Germany Dueren, Germany Frankfurt, Germany Halle, Germany Mainz, Germany Less <<
NCT00153946	Stroke	Phase 4	Completed	-	Japan ... More >> EAST Study Office c/o National Cardiovascular Center Suita, Osaka, Japan, 565-8565 Less <<
NCT00035178	Kidney Failure, Chronic\|Renal ... More >>Disease, End-Stage Less <<	PHASE4	COMPLETED	2025-11-02	University of Chicago, Section... More >> of Nephrology, Chicago, Illinois, 60637, United States\|DaVita Clinical Research, Minneapolis, Minnesota, 55404, United States Less <<
NCT00039858	Thrombocytopenia\|Thrombosis	PHASE4	COMPLETED	2025-03-06	Mattel Children's Hospital at ... More >>UCLA, Los Angeles, California, 90095, United States\|Children's Hospital of Orange County, Orange, California, 92868, United States\|Rush University Medical Center, Chicago, Illinois, 60612, United States\|University of Chicago Children's Hospital, Chicago, Illinois, 60637, United States\|Children's Hospital of Illinois, Peoria, Illinois, 61614, United States\|Kosair Children's Hospital, University of Louisville, Louisville, Kentucky, 40202, United States\|Children's Hospital of Boston, Boston, Massachusetts, 02115, United States\|Michigan Congenital Heart Center, Ann Arbor, Michigan, 48109, United States\|Rainbow Babies at Children's Hospital, Cleveland, Ohio, 44106, United States\|Oregon Health & Science University, Portland, Oregon, 97201, United States\|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, United States\|Primary Children's Medical Center, Salt Lake City, Utah, 84113, United States\|Children's Hospital and Regional Medical Center, Seattle, Washington, 98105, United States Less <<
NCT00508924	-		Completed	-	-
NCT00798525	Heparin Induced Thrombocytopen... More >>ia (HIT) Less <<	Phase 4	Terminated(Supply of Lepirudin... More >> ended on 01. April 2012, thus trial terminated on 31. March 2012) Less <<	-	Germany ... More >> Universitätsklinikum Düsseldorf Klinik für Anästhesiologie Düsseldorf, Germany, 40225 Less <<
NCT00198588	Heparin-Induced Thrombocytopen... More >>ia Less <<	Phase 3	Completed	-	Japan ... More >> National Hospital Organization Nagoya Medical Center Nagoya, Aichi, Japan, 4600001 Nagoya University Hospital Nagoya, Aichi, Japan, 4668560 Nagoya Daini Red Cross Hospital Nagoya, Aichi, Japan, 4668650 National Hospital Organization Hakodate National Hospital Hakodate, Hokkaido, Japan, 0418512 National Hospital Organization Hokkaido Cancer Center Sapporo, Hokkaido, Japan, 0030804 Kurume University Hospital Kurume, Hukuoka, Japan, 8300011 Kobe University Hospital Kobe, Hyogo, Japan, 6500017 Kobe City General Hospital Kobe, Hyogo, Japan, 6500046 Iwate Medical University Hospital Morioka, Iwate, Japan, 0208505 Tokai University Hospital Isehara, Kanagawa, Japan, 2591193 Mie University Hospital Tsu, Mie, Japan, 5148507 National Cardiovascular Center Suita, Osaka, Japan, 5658565 Sakakibara Memorial Hospital Fuchu, Tokyo, Japan, 1830003 National Hospital Organization Iwakuni Clinical Center Iwakuni, Yamaguchi, Japan, 7408510 Yamaguchi University Hospital Ube, Yamaguchi, Japan, 7558505 Kyoto Second Red Cross Hospital Kyoto, Japan, 6028026 Kyoto University Hospital Kyoto, Japan, 6068507 The University of Tokyo Hospital Tokyo, Japan, 1138655 National Hospital Organization Tokyo Medical Center Tokyo, Japan, 1528902 Keio University Hospital Tokyo, Japan, 1608582 Less <<
NCT00787332	-		Terminated(Low enrollment)	-	-
NCT00861692	Heparin-induced Thrombocytopen... More >>ia Type II Less <<	Phase 2	Completed	-	France ... More >> Saint Etienne, France Less <<
NCT01246011	-		Terminated(Enrollment was too ... More >>slow.) Less <<	-	-
NCT00787332	Suspected Heparin-Induced Thro... More >>mbocytopenia Less <<	Phase 4	Terminated(Low enrollment)	-	-
NCT00268762	Ischemic Stroke	Phase 1 Phase 2	Completed	-	United States, Alabama ... More >> University of Alabama-Birmingham Birmingham, Alabama, United States, 35249 United States, California Cedars-Sinai Medical Center Los Angeles, California, United States, 90048 United States, Louisiana Tulane University New Orleans, Louisiana, United States, 70112 United States, Texas University of Texas-Southwestern Dallas Dallas, Texas, United States, 75390 Memorial Hermann Hospital-Medical Center Houston, Texas, United States, 77030 Memorial Hermann Southwest Hospital Houston, Texas, United States, 77074 Less <<
NCT00268762	-		Completed	-	-
NCT01246011	Coronary Artery Bypass Graft S... More >>urgery Presence of Heparin/Platelet Factor 4 Antibody Less <<	Phase 4	Terminated(Enrollment was too ... More >>slow.) Less <<	-	United States, Massachusetts ... More >> Massachusetts General Hospital Boston, Massachusetts, United States, 02474 Less <<
NCT01163604	CVD	Phase 4	Completed	-	China, Jiangsu ... More >> Department of Neurology, Jinling Hospital, Nanjing University School of Medicine Nanjing, Jiangsu, China, 210002 Less <<
NCT01464788	-		Terminated(The study was halte... More >>d prematurely at 90 of 105 planned patients due to the beneficial results of embolectomy clinical trials.) Less <<	-	-
NCT01734252	Achievement of a Sufficient Th... More >>rombosis Prohpylaxis in Clitically Ill Patients With Heparin Resistance Less <<	PHASE2	COMPLETED	2016-04-01	Medical University Innsbruck /... More >> Department for General and Surgical Intensive Care Medicine, Innsbruck, 6020, Austria Less <<
NCT03552354	Stroke, Ischemic	Phase 4	Recruiting	January 8, 2019	China, Liaoning ... More >> General Hospital of Shenyang Military Region Recruiting Shenyang, Liaoning, China, 10016 Contact: Hui-sheng Chen, Doctor Less <<
NCT00861692	-		Completed	-	-
NCT01464788	Ischemic Stroke	Phase 2	Terminated(The study was halte... More >>d prematurely at 90 of 105 planned patients due to the beneficial results of embolectomy clinical trials.) Less <<	-	United States, Texas ... More >> University of Texas Health Science Center at Houston Houston, Texas, United States, 77030 Less <<
NCT02448069	Stroke\|Cerebral Ischemia	PHASE2	COMPLETED	2025-08-16	University of Texas Health Sci... More >>ence Center at Houston, Houston, Texas, 77030, United States Less <<
NCT01163604	-		Completed	-	-
NCT03740958	Stroke	Phase 4	Not yet recruiting	June 30, 2021	-
NCT01980316	CVD	Phase 4	Completed	-	China, Jiangsu ... More >> Department of Neurology, Jinling Hospital, Nanjing University School of Medicine Nanjing, Jiangsu, China, 210009 Less <<
NCT03506009	Argatroban, Rt-PA	Phase 4	Terminated(it is very difficul... More >>t to recruit qualified patients) Less <<	-	China, Liaoning ... More >> General Hospital of Shenyang Military Region Shenyang, Liaoning, China, 10016 Less <<
NCT04275180	Acute Progressive Ischemic Str... More >>oke Less <<	PHASE4	COMPLETED	2023-01-31	Min Lou, Hangzhou, Zhejiang, 3... More >>10000, China\|People's Hospital of Anji, Anji, China\|Jiaxing Second Hospital, Jiaxing, China\|Ninghai First Hospital, Ninghai, China\|Quzhou Kecheng People's Hospital, Quzhou, China\|Tongxiang Diyi Renmin Hospital, Tongxiang, China Less <<
NCT05740371	Stable Coronary Artery Disease... More >> (CAD)\|Unstable Angina (Troponin Negative) Less <<	PHASE4	COMPLETED	2021-05-06	University Hospital Frankfurt,... More >> Frankfurt am Main, Hessen, 60590, Germany\|Herz-Kreislauf-Zentrum Klinikum Hersfeld-Rotenburg, Rotenburg an der Fulda, Hessen, 36199, Germany Less <<

{[proInfo.proName]}

CAS No.: 74863-84-6

{[proInfo.proName]}

CAS No.: 74863-84-6

Alternative Products

Product Details of Argatroban

Safety of Argatroban

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	1.97mL 0.39mL 0.20mL	9.83mL 1.97mL 0.98mL	19.66mL 3.93mL 1.97mL
Dissolving Methods	Animal experiment Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn: in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1 Protocol 2

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed